News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Neumedicines Inc.’ Study Shows HemaMax, Not Neupogen (G-CSF), Improves Survival Outcomes Following Lethal Irradiation


1/8/2014 9:06:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PASADENA, Calif.--(BUSINESS WIRE)--Neumedicines Inc., a privately held company developing therapies based on interleukin-12 (IL-12) as a radiation medical countermeasure and as a hematopoietic immunotherapeutic (HIT) for use in cancer patients, today announced results from a blinded, randomized, placebo-controlled study that demonstrate a significant increase in survival in non-human primates treated with a single, low-dose, subcutaneous injection of HemaMax™ (recombinant human interleukin-12) versus control (56% versus 36%; p<0.05) 60 days after exposure to lethal radiation.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES